Pluvicto Prior to Taxane Therapy Prolongs rPFS
Results presented by Dr. Oliver Sartor on October 23 at the 2023 European Society for Medical Oncology (ESMO) Congress showed that:
- The PSMAfore Phase 3 trial of 177Lu-PSMA-617 met its primary endpoint of radiographic progression-free survival (HR 0.41, 95% CI 0.29 to 0.56). Indeed, 177Lu-PSMA-617 more than doubled median radiographic progression-free survival to 12.0 months versus 5.6 months for change in androgen receptor pathway inhibitors (ARPIs).
- 177Lu-PSMA-617 also showed improved (more than or equal 50%) decline in prostate-specific antigen, improved objective response rate, improved duration of response and improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints.
- PSMAfore continues to collect OS data.
These results show that in men with PSMA-positive metastatic castration-resistant prostate cancer who have progressed on prior ARPI, 177Lu-PSMA-617 prior to taxane therapy prolongs radiographic progression-free survival compared with change in ARPI.
A Few Useful Links regarding 177Lu-PSMA-617 therapy:
Guidelines on 177Lu-PSMA-617 therapy: https://tinyurl.com/ACNM177LuPSMA617
Consensus Statements/ Recommendations: